Clinical Trial Results:
Multicenter, semi-blinded, randomized, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for the delineation of primary and recurrent tumor and metastases in patients undergoing curative surgery for colorectal cancer.
|
Summary
|
|
EudraCT number |
2018-000151-40 |
Trial protocol |
DE NL IT |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Mar 2026
|
First version publication date |
12 Mar 2026
|
Other versions |
|
Summary report(s) |
SGM-CLIN03 Summary of Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.